PharmaCyte Biotech Inc (PMCB)

[$Pistol Pete$]

In total, 27 patients with advanced, inoperable pancreatic cancer have been treated with the Cell-in-a-Box(R)/ifosfamide combination - 14 in the Phase 1/2 clinical trial and 13 in the second Phase 2 clinical trial. Both trials were uncontrolled (no comparator arms), open-label studies. In each of the clinical trials, a single implantation of Cell-in-Box(R) capsules (each capsule contained approximately 10,000 cells capable of converting the anticancer prodrug ifosfamide into its "cancer-killing" form by virtue of their over-expression of an isoform [CYP2B1] of human cytochrome P450) was used and two courses of treatment with ifosfamide were administered. In both clinical trials, there were no deleterious effects, such as inflammation or pancreatitis, that could be attributed to the Cell-in-a-Box(R) capsules being implanted in the patients.



$NVLX

Pistol Pete!